11:20 AM EDT, 05/15/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Wednesday it has dosed the last patient in its phase 2 Karisma-Endoxifen clinical study.

The trial, with 240 participants, is evaluating selective estrogen receptor modulator (Z)-endoxifen in premenopausal women with measurable mammographic breast density, the biopharmaceutical company added.

The patients were given 1 mg and 2 mg doses of (Z)-endoxifen daily for six months, Atossa said.

Shares of the company rose 7.5% in recent trading.

Price: 1.66, Change: +0.12, Percent Change: +7.47